Literature DB >> 3086885

Activation of human peripheral blood mononuclear cells by anti-T3: killing of tumor target cells coated with anti-target-anti-T3 conjugates.

G Jung, C J Honsik, R A Reisfeld, H J Müller-Eberhard.   

Abstract

Cytotoxic T-cell clones have been shown to be capable of killing unrelated target cells in the presence of heteroconjugates consisting of OKT3 (monoclonal antibody against cell surface antigen T3) and targeting antibody. In contrast, human peripheral blood T cells were not known to have this ability, although these cells have been shown to undergo proliferation in response to OKT3 and accessory signals. Here we report that OKT3-stimulated human peripheral blood mononuclear cells effectively killed human melanoma or Raji cells coated with anti-target-cell--OKT3 conjugates. The extent of target-cell killing by stimulated effector cells was much greater than that observed with unstimulated cells, in spite of down-regulation of the T3 structure on the OKT3-treated cells. Target-cell lysis occurred at physiological concentrations of effector cells and was inhibited by monomeric OKT3, indicating that killing was T-cell-mediated.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3086885      PMCID: PMC323757          DOI: 10.1073/pnas.83.12.4479

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  18 in total

1.  Induction of nonspecific cytotoxicity by monoclonal anti-T3 antibodies.

Authors:  J F Leeuwenberg; H Spits; W J Tax; P J Capel
Journal:  J Immunol       Date:  1985-06       Impact factor: 5.422

2.  Heteroantibody duplexes target cells for lysis by cytotoxic T lymphocytes.

Authors:  M A Liu; D M Kranz; J T Kurnick; L A Boyle; R Levy; H N Eisen
Journal:  Proc Natl Acad Sci U S A       Date:  1985-12       Impact factor: 11.205

3.  Hybrid antibodies can target sites for attack by T cells.

Authors:  U D Staerz; O Kanagawa; M J Bevan
Journal:  Nature       Date:  1985 Apr 18-24       Impact factor: 49.962

4.  Attachment of an anti-receptor antibody to non-target cells renders them susceptible to lysis by a clone of cytotoxic T lymphocytes.

Authors:  D M Kranz; S Tonegawa; H N Eisen
Journal:  Proc Natl Acad Sci U S A       Date:  1984-12       Impact factor: 11.205

5.  OKT3: a monoclonal anti-human T lymphocyte antibody with potent mitogenic properties.

Authors:  J P Van Wauwe; J R De Mey; J G Goossens
Journal:  J Immunol       Date:  1980-06       Impact factor: 5.422

6.  Triggering of the T3-Ti antigen-receptor complex results in clonal T-cell proliferation through an interleukin 2-dependent autocrine pathway.

Authors:  S C Meuer; R E Hussey; D A Cantrell; J C Hodgdon; S F Schlossman; K A Smith; E L Reinherz
Journal:  Proc Natl Acad Sci U S A       Date:  1984-03       Impact factor: 11.205

7.  Unique glycoprotein-proteoglycan complex defined by monoclonal antibody on human melanoma cells.

Authors:  T F Bumol; R A Reisfeld
Journal:  Proc Natl Acad Sci U S A       Date:  1982-02       Impact factor: 11.205

8.  Evidence for the T3-associated 90K heterodimer as the T-cell antigen receptor.

Authors:  S C Meuer; O Acuto; R E Hussey; J C Hodgdon; K A Fitzgerald; S F Schlossman; E L Reinherz
Journal:  Nature       Date:  1983-06-30       Impact factor: 49.962

9.  Protein thiolation and reversible protein-protein conjugation. N-Succinimidyl 3-(2-pyridyldithio)propionate, a new heterobifunctional reagent.

Authors:  J Carlsson; H Drevin; R Axén
Journal:  Biochem J       Date:  1978-09-01       Impact factor: 3.857

10.  Human in vivo antigenic modulation induced by the anti-T cell OKT3 monoclonal antibody.

Authors:  L Chatenoud; M F Baudrihaye; H Kreis; G Goldstein; J Schindler; J F Bach
Journal:  Eur J Immunol       Date:  1982-11       Impact factor: 5.532

View more
  19 in total

1.  Targeting of T-B interaction using heteroconjugate antibody.

Authors:  J L Davignon; M Vallin-Davignon; P L Cohen; R A Eisenberg
Journal:  Immunology       Date:  1991-05       Impact factor: 7.397

Review 2.  Bispecific antibody: a tool for diagnosis and treatment of disease.

Authors:  S Songsivilai; P J Lachmann
Journal:  Clin Exp Immunol       Date:  1990-03       Impact factor: 4.330

3.  Preparation of monoclonal anti-porcine CD3 antibodies and preliminary characterization of porcine T lymphocytes.

Authors:  H Yang; C A Oura; P A Kirkham; R M Parkhouse
Journal:  Immunology       Date:  1996-08       Impact factor: 7.397

4.  Preparation and analysis of bifunctional immunoconjugates containing monoclonal antibodies OKT3 and BABR1.

Authors:  P D Foglesong; M A Winkler; J O Price; G D Marshall; S H Reagh; D A Bush; K S Hixson; W H West
Journal:  Cancer Immunol Immunother       Date:  1989       Impact factor: 6.968

5.  The cytolytic protein of human lymphocytes related to the ninth component (C9) of human complement: isolation from anti-CD3-activated peripheral blood mononuclear cells.

Authors:  L S Zalman; D E Martin; G Jung; H J Müller-Eberhard
Journal:  Proc Natl Acad Sci U S A       Date:  1987-04       Impact factor: 11.205

6.  Induction of expression of cell-surface homologous restriction factor upon anti-CD3 stimulation of human peripheral lymphocytes.

Authors:  D E Martin; L S Zalman; H J Müller-Eberhard
Journal:  Proc Natl Acad Sci U S A       Date:  1988-01       Impact factor: 11.205

7.  Induction of cytotoxicity in resting human T lymphocytes bound to tumor cells by antibody heteroconjugates.

Authors:  G Jung; J A Ledbetter; H J Müller-Eberhard
Journal:  Proc Natl Acad Sci U S A       Date:  1987-07       Impact factor: 11.205

Review 8.  Bispecific antibodies and CARs: generalized immunotherapeutics harnessing T cell redirection.

Authors:  Eugene A Zhukovsky; Richard J Morse; Marcela V Maus
Journal:  Curr Opin Immunol       Date:  2016-03-08       Impact factor: 7.486

9.  Enhancement of the lytic activity of cloned human CD8 tumour-infiltrating lymphocytes by bispecific monoclonal antibodies.

Authors:  A Gorter; K M Krüse; P I Schrier; G J Fleuren; R J van de Griend
Journal:  Clin Exp Immunol       Date:  1992-01       Impact factor: 4.330

Review 10.  Human autologous tumor-specific T cells in malignant melanoma.

Authors:  C D Platsoucas
Journal:  Cancer Metastasis Rev       Date:  1991-06       Impact factor: 9.264

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.